| アブストラクト | BACKGROUND: Japan's super-aged society presents significant challenges, particularly with regard to managing aspiration pneumonia among older adults. We aimed to investigate the link between anticholinergic drug use and the incidence of aspiration pneumonia, primarily utilizing data from the Japanese Adverse Drug Event Report (JADER) database. METHODS: The primarily analysis included JADER data from the first quarter of 2004 through the third quarter of 2023, focusing on 2367 cases of aspiration pneumonia in individuals aged >/=60 years. The study examined the association of aspiration pneumonia with 49 drugs listed in the Anticholinergic Risk Scale, using the Reporting Odds Ratio for signal detection. A scoping review incorporating findings from MEDLINE and the Cochrane Library was conducted to validate these associations. RESULTS: The primary analysis identified an increased risk of aspiration pneumonia associated with specific drugs, including clozapine, haloperidol, risperidone, quetiapine, and olanzapine. A total of 20 drugs were significantly associated with an increased risk of aspiration pneumonia. Our results emphasize the importance of considering the dopamine-blocking effects of these drugs, particularly in at-risk populations, such as older adults, and those with conditions, such as schizophrenia or Parkinson's disease. CONCLUSIONS: The study highlights the importance of careful monitoring of anticholinergic drugs with potent dopamine-blocking effects, such as clozapine, haloperidol, risperidone, quetiapine, and olanzapine, to reduce the risk of aspiration pneumonia. Future research should include observational and interventional studies to further investigate these findings. ETHICS AND DISSEMINATION: As this study utilized pre-existing anonymized information, approval from an ethics committee was not required. |
|---|
| ジャーナル名 | Respiratory investigation |
|---|
| 投稿日 | 2024/9/11 |
|---|
| 投稿者 | Ueda, Akihito; Nohara, Kanji; Obara, Michiko; Watanabe, Shinichi |
|---|
| 組織名 | Doctoral Program in Pharmaceutical Sciences, Graduate School of Pharmaceutical;Sciences, Teikyo Heisei University, Tokyo, Japan; Medical Corporation Toujinkai,;Fujitate Hospital, Osaka, Japan. Electronic address: akihitoueda@gmail.com.;Department of Rehabilitation for Orofacial Disorders, Osaka University Graduate;School of Dentistry, Osaka, Japan.;Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39260157/ |
|---|
